SASKATOON, FRIDAY, AUGUST 22, 2014 - Today, CanniMed Ltd. is pleased to introduce another two varieties to their existing supply of consistent medical marijuana: CanniMed 15·5 (now available to order) and CanniMed 4·10 (available in October).
“Since the announcement of the Marihuana for Medical Purposes Regulations (MMPR), our goal has been to deliver a consistent and reliable supply of medical marijuana to our patients,” said Brent Zettl, President and CEO of CanniMed.
There is evidence suggesting that the amount of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a medical marijuana product has a bearing on its effect for different conditions, but it’s not just absolute concentration that matters. The ratio of THC and CBD is also critical because there is evidence that the two compounds may work synergistically.
CanniMed products provide patients with seven distinct THC to CBD ratios to help with their medical needs:
Since November 2013, CanniMed has been seamlessly fulfilling patient orders within 48 hours of their medical authorization forms arriving. With the addition of the two additional varieties, CanniMed commits to continue with this seamless customer service.